81 related articles for article (PubMed ID: 31036830)
21. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
23. ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro.
Chen Y; Zou H; Yang LY; Li Y; Wang L; Hao Y; Yang JL
Asian Pac J Cancer Prev; 2012; 13(5):2385-92. PubMed ID: 22901226
[TBL] [Abstract][Full Text] [Related]
24. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
Yang S; Lee JY; Hur H; Oh JH; Kim MH
BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
[TBL] [Abstract][Full Text] [Related]
28. GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
Yin H; Zhu Q; Liu M; Tu G; Li Q; Yuan J; Wen S; Yang G
Int J Oncol; 2017 Oct; 51(4):1191-1198. PubMed ID: 28902352
[TBL] [Abstract][Full Text] [Related]
29. MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression.
Zou R; Zhong X; Wang C; Sun H; Wang S; Lin L; Sun S; Tong C; Luo H; Gao P; Li Y; Zhou T; Li D; Cao L; Zhao Y
Int J Biol Sci; 2015; 11(9):992-1005. PubMed ID: 26221067
[TBL] [Abstract][Full Text] [Related]
30. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
31. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
32. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
Wu H; Li J; Guo E; Luo S; Wang G
Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
[TBL] [Abstract][Full Text] [Related]
33. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
34. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
35. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor positive breast tumors resist chemotherapy by the overexpression of P53 in Cancer Stem Cells.
Ashour F; Awwad MH; Sharawy HEL; Kamal M
J Egypt Natl Canc Inst; 2018 Jun; 30(2):45-48. PubMed ID: 29779937
[TBL] [Abstract][Full Text] [Related]
37. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC.
Petrovic N; Sami A; Martinovic J; Zaric M; Nakashidze I; Lukic S; Jovanovic-Cupic S
Pathol Res Pract; 2017 Oct; 213(10):1264-1270. PubMed ID: 28935174
[TBL] [Abstract][Full Text] [Related]
38. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA
Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906
[TBL] [Abstract][Full Text] [Related]
40. Expression of CYB5D2 is associated with epithelial-mesenchymal transition and survival rates in patients with cervical cancer.
Li D; Qiu B; Chen X; Hu L; Wen L; Wei F
Transl Cancer Res; 2020 Feb; 9(2):1185-1194. PubMed ID: 35117463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]